Business Context and Reporting Period
This filing is a Form 13F Information Table submitted by Takeda Pharmaceutical Co Ltd for the reporting period ending June 30, 2024. The document discloses the company's holdings in equity securities as required by the U.S. Securities and Exchange Commission.
Key Financial Metrics and Holdings
The filing details specific equity positions rather than the company's consolidated financial performance. Key metrics include the number of shares held, value of holdings, and voting authority for the following issuers:
| Issuer | Shares Held | Value (USD) | Voting Authority |
|---|---|---|---|
| Denali Therapeutics Inc. | 97,862,060 | $4,214,559 | Sole |
| HilleVax, Inc. | 97,229,440 | $6,724,000 | Discretionary |
| Phathom Pharmaceuticals, Inc. | 16,037,749 | $1,557,063 | Sole |
| Ovid Therapeutics Inc. | 5,792,461 (Total) | $7,531,996 (Total) | Discretionary & Sole |
| Equillium, Inc. | 1,259,234 | $1,824,977 | Discretionary |
| American Well Corp | 505,267 | $1,554,669 | Discretionary |
| Xilio Therapeutics, Inc. | 1,398,415 | $1,475,121 | Discretionary |
| Wave Life Sciences Ltd. | 6,720,991 (Total) | $1,346,892 (Total) | Discretionary & Sole |
| Turnstone Biologics Corp. | 2,347,060 | $895,824 | Discretionary |
| Akili, Inc. | 321,386 | $738,819 | Discretionary |
| Shattuck Labs, Inc. | 1,990,289 | $515,619 | Discretionary |
| Rani Therapeutics Holdings, Inc. | 817,654 | $215,172 | Discretionary |
| Standard BioTools Inc. | 29,232 | $16,515 | Discretionary |
Note: Revenue, profit, cash flow, margins, debt, and liquidity metrics for Takeda Pharmaceutical Co Ltd are not provided in this filing.
Material Changes
The filing text does not provide comparative data for the prior quarter or year-over-year changes. Therefore, material changes in holdings versus the prior comparable period cannot be determined from this document alone.
Guidance, Outlook, and Risks
This Form 13F is a regulatory disclosure of holdings and does not contain management commentary, financial guidance, outlook, or specific risk factors regarding Takeda's operations. The filing includes a standard disclaimer that the SEC has not reviewed the information for accuracy or completeness.
Important Facts for Investors to Verify
- Portfolio Concentration: Verify the total value of Takeda's disclosed holdings against its total assets to understand the significance of these specific positions.
- Voting Authority: Note the distinction between "Sole" and "Discretionary" voting authority, particularly for large positions like Denali Therapeutics and HilleVax.
- Valuation Basis: Confirm that the reported values are based on the nearest dollar as of the reporting date (June 30, 2024) and may differ from current market prices.
- Missing Financials: Recognize that this document does not reflect Takeda's own financial health (revenue, earnings, debt) and should be cross-referenced with Form 10-K or 10-Q filings for that data.